ClinicalTrials.Veeva

Menu
M

Miami Clinical Research | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SPN-810
SPN-812
NX-13
BOS-580
Rocatinlimab
Apixaban
HU6
AMG 451
S-217622

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 14 total trials

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

This is a safety study to evaluate BOS-580 administered subcutaneously with repeated dosing over 12 weeks in Part A or 24 weeks in Part B. Part C is...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine
Status recently updated

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Enrolling
Active, not recruiting
Fatty Liver
Nonalcoholic Steatohepatitis
Drug: HU6
Other: Placebo

Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).

Enrolling
Ulcerative Colitis
Drug: NX-13 Placebo
Drug: NX-13 250mg

An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent s...

Enrolling
Clostridoides Difficile Associated Disease
Biological: C. difficile vaccine (previously studied formulation).
Biological: C. difficile vaccine formulation 1.

Trial sponsors

BioNTech logo
Moderna logo
Supernus Pharmaceuticals logo
A
Amgen logo
Boston Scientific logo
Janssen (J&J Innovative Medicine) logo
L
Pfizer logo
Rivus Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems